Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Melio Bio, a biotech dedicated to the discovery and development of novel inhibitors targeting a receptor implicated in obesity and associated co-morbidities, has been revealed as the winner of Pioneer ...

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

Novo Nordisk boasts 45 million customers using its drug, which has caused a revolution in weight-loss treatment. But competitors are nipping at its heels.

Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment.

Novo Nordisk is also developing an oral drug for obesity, amycretin, which also performed better than Wegovy in a phase 3 obesity trial and is in mid-stage development. New approval for Zepbound ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Saxenda continues to develop a dominant position in obesity pharmacotherapy however, and Novo Nordisk said the drug currently has a market share of 63% worldwide. The company’s GLP-1 agonists ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Vials of Wegovy at a Novo Nordisk production line in Hillerod, Denmark. The company argues government subsidies for its weight-loss drugs will help Australia tackle obesity. Bloomberg “Novo ...